Despite the SUR2 gain-of-function mutation being a cause of cardiovascular abnormalities observed in patients with Cantu syndrome, our results showed that pharmacological activation of SUR2 should be considered for treating PAH. Here, ABCC9 is linked to pulmonary arterial hypertension.